Biologics for the treatment of severe asthma : Current status report 2023
Severe asthma is associated with increased use of healthcare services, significant deterioration in the quality of life, and high disease and economic burden on patients and societies. Additional treatments are required for severe forms of asthma. Biological agents are recommended for the treatment of severe asthma. In this current status report, we aimed to evaluate the efficacy, effectiveness, and safety data of approved biologics; omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, in the treatment of severe asthma and appropriate patient profiles for these biologics. Pubmed and Cochrane databases based on randomized controlled trials, posthoc analyses, meta-analyses, and real-life studies examining the efficacy and effectiveness of biologics in severe asthma were searched, and the results of these studies on important asthma outcomes were reviewed. Existing studies have shown that all the approved biologic agents targeting cells, receptors, and mediators involved in type 2 inflammation in the bronchial wall in severe asthma significantly reduce asthma exacerbations, reduce the need for oral corticosteroids, and improve asthma control, quality of life, and pulmonary functions. Characterizing the asthma endotype and phenotype in patients with severe asthma and determining which treatment would be more appropriate for a particular patient is an essential step in personalized treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Tuberkuloz ve toraks - 71(2023), 2 vom: 01. Juni, Seite 176-187 |
| Sprache: |
Türkisch |
|---|
| Weiterer Titel: |
Ağır astım tedavisinde biyolojikler: Güncel durum raporu 2023 |
|---|
| Beteiligte Personen: |
Paçacı Çetin, Gülden [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2P471X1Z11 |
|---|
| Anmerkungen: |
Date Completed 23.06.2023 Date Revised 01.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5578/tt.20239921 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35846840X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35846840X | ||
| 003 | DE-627 | ||
| 005 | 20240301231951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||tur c | ||
| 024 | 7 | |a 10.5578/tt.20239921 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM35846840X | ||
| 035 | |a (NLM)37345400 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a tur | ||
| 100 | 1 | |a Paçacı Çetin, Gülden |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biologics for the treatment of severe asthma |b Current status report 2023 |
| 246 | 3 | 3 | |a Ağır astım tedavisinde biyolojikler: Güncel durum raporu 2023 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2023 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe asthma is associated with increased use of healthcare services, significant deterioration in the quality of life, and high disease and economic burden on patients and societies. Additional treatments are required for severe forms of asthma. Biological agents are recommended for the treatment of severe asthma. In this current status report, we aimed to evaluate the efficacy, effectiveness, and safety data of approved biologics; omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, in the treatment of severe asthma and appropriate patient profiles for these biologics. Pubmed and Cochrane databases based on randomized controlled trials, posthoc analyses, meta-analyses, and real-life studies examining the efficacy and effectiveness of biologics in severe asthma were searched, and the results of these studies on important asthma outcomes were reviewed. Existing studies have shown that all the approved biologic agents targeting cells, receptors, and mediators involved in type 2 inflammation in the bronchial wall in severe asthma significantly reduce asthma exacerbations, reduce the need for oral corticosteroids, and improve asthma control, quality of life, and pulmonary functions. Characterizing the asthma endotype and phenotype in patients with severe asthma and determining which treatment would be more appropriate for a particular patient is an essential step in personalized treatment | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Omalizumab |2 NLM | |
| 650 | 7 | |a 2P471X1Z11 |2 NLM | |
| 700 | 1 | |a Kepil Özdemir, Seçil |e verfasserin |4 aut | |
| 700 | 1 | |a Can Bostan, Özge |e verfasserin |4 aut | |
| 700 | 1 | |a Öztop, Nida |e verfasserin |4 aut | |
| 700 | 1 | |a Çelebi Sözener, Zeynep |e verfasserin |4 aut | |
| 700 | 1 | |a Karakaya, Gül |e verfasserin |4 aut | |
| 700 | 1 | |a Gelincik Akkor, Aslı |e verfasserin |4 aut | |
| 700 | 1 | |a Yılmaz, İnsu |e verfasserin |4 aut | |
| 700 | 1 | |a Mungan, Dilşad |e verfasserin |4 aut | |
| 700 | 1 | |a Bavbek, Sevim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberkuloz ve toraks |d 2003 |g 71(2023), 2 vom: 01. Juni, Seite 176-187 |w (DE-627)NLM147934990 |x 2980-3187 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2023 |g number:2 |g day:01 |g month:06 |g pages:176-187 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5578/tt.20239921 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2023 |e 2 |b 01 |c 06 |h 176-187 | ||